menu
close
Toll-Free 1-866-625-9854

Flagenase 400 (Metronidazole, Diiodohydroxyquinoline)

Active Ingredient: Metronidazole, Diiodohydroxyquinoline
Dosage: 400 mg / 200 mg
Route of Administration: Oral
Dosage Form: Suspension
Quantity per package: 120 ml
Availability: Out of stock

Why is Flagenase 400 not sold in the USA?

Flagenase 400 is not used in the USA mainly because the combination of Metronidazole with Diiodohydroxyquinoline is not approved by the U.S. Food and Drug Administration (FDA). The FDA has rigorous safety and efficacy standards that must be met through extensive clinical trials, and this specific combination may not have been studied or approved for use in the US market.

What alternatives to Flagenase 400 are used in the USA?

Here are similar drugs available in the USA that are used to treat the same diseases and symptoms as Flagenase 400, categorized based on their antimicrobial and antiprotozoal properties:

Antiprotozoal Drugs:

Broad-Spectrum Antibiotics for Various Infections:

Specialized Treatments for Specific Infections:

See also  Vikrol (Clarithromycin)

What is Flagenase 400?

Flagenase 400 is a medication used to treat amoebiasis, infections of the gum and dental cavities, pelvic area infection, brain infection, lung infection, bone infections, stomach infections, intestinal infection, genital tract infection, blood infection, and other conditions.

Indications

  • Treatment of intraintestinal and extraintestinal amebiasis;
  • Amebic liver abscess.

Popularity in Various Countries

Flagenase 400 is popular in several Latin American countries and some parts of Asia and Africa where infections caused by protozoa and anaerobic bacteria are more common. The reasons for its popularity include:

  1. High Incidence of Parasitic Infections: These regions may have higher rates of waterborne and foodborne illnesses, including amoebiasis.
  2. Cost-Effectiveness: Flagenase 400 is an affordable treatment option in these countries.
  3. Proven Efficacy: The combination of active ingredients in Flagenase 400 makes it highly effective against a wide range of infections, which appeals in areas with diverse microbial and protozoal challenges.

Dosage and administration

Children from 1 to 9 years: The dose will be calculated at the rate of 40 mg of metronidazole and diiodohydroxyquinoline per kg of weight/day divided into 3 doses per day for 10 days. The average dose is 125 to 250 mg (1 to 2 teaspoons every 8 hours). The maximum dose is 1.25 g / day divided in 3 doses. One teaspoon of 5 mL is = 125 mg of metronidazole and 100 mg of diiodohydroxyquinoline.

See also  Ampliron (Amoxicillin)

Contraindications

  • Hypersensitivity to metronidazole;
  • Consumption of alcohol, coumarin anticoagulants or disulfiram;
  • History of blood dyscrasias;
  • Hypersensitivity to any 8-hydroxyquinoline or preparations containing iodine;
  • Previous liver damage.

Side effects

In some cases, Flagenase 400 can cause:

  • epigastric pain;
  • nausea;
  • vomiting;
  • diarrhea;
  • oral mucositis;
  • taste disorders, including metallic taste;
  • anorexia;
  • erythema;
  • pruritus;
  • flushing;
  • hives;
  • fever;
  • angioedema;
  • anaphylactic shock;
  • peripheral sensory neuropathy;
  • headache;
  • seizures;
  • vertigo;
  • psychotic disorders including confusion, hallucinations, depressive mood;
  • temporary visual disorders such as diplopia and myopia.

Overdose

There is no specific antidote for Flagenase 400. The administration of diiodohydroxyquinoline in doses> at 2 g per day for long periods can be associated with significantly greater risks of producing toxic effects. The treatment of overdose with metronidazole and diiodohydroxyquinoline should be symptomatic, with general support measures and gastric lavage.

Interaction

Concomitant use of metronidazole with warfarin inhibits its metabolism and may cause bleeding. Co-administration with disulfiram can cause acute psychosis or confusional state. Co-administration with ethanol palpitations causes tachycardia, nausea and vomiting. Barbiturates induce therapeutic failure by shortening the half-life of metronidazole, in which case the initial dose of metronidazole will be increased. The simultaneous use of cimetidine can decrease the hepatic metabolism of metronidazole, so it delays its elimination, increases its serum concentration and its potential toxicity. Phenobarbital increases the biotransformation of metronidazole, which decreases its half-life. Metronidazole inhibits the clearance of diphenylhydantoin by increasing its serum concentration.